Dr. Jacob Taylor is a board-certified urologic oncologist dedicated to providing comprehensive, cutting-edge care for patients with urologic cancers. Dr. Taylor completed his undergraduate education at the University of Rochester, where he also earned a Master of Public Health degree. He received his medical degree from Albert Einstein College of Medicine and went on to complete his general surgery internship and urology residency at New York Langone Health Medical Center.

Following his residency, Dr. Taylor pursued advanced training in urologic oncology at UT Southwestern Medical Center in Dallas, where he completed a prestigious two-year Society of Urologic Oncology fellowship. During this time, he gained expertise in complex open and minimally invasive surgeries. Dr. Taylor believes in multi-modal personalized care. “Cancer care is deeply personal, and every patient brings their own values, goals, and concerns to the table,” says Dr. Taylor. “It’s my responsibility to listen and ensure that the treatment plan aligns not only with the latest evidence-based practices, but also with what matters most to the patient. I want my patients to feel empowered in their care, knowing that their quality of life, preferences, and long-term well-being are the foundation of every decision.”

Dr. Taylor believes in presenting options for patients, and adjusting treatment plans to each patient’s unique cancer profile. “We’ve moved beyond a ‘one-size-fits-all’ approach to cancer care. Today, we can offer highly individualized, multi-modal treatment options that give patients the best chance for a successful outcome while also prioritizing their overall health and life goals.”

With a strong commitment to advancing the field of urology, Dr. Taylor has published more than 40 peer-reviewed articles and book chapters. His research interests span a broad range of topics, including innovative cancer therapies and optimizing surgical outcomes. Dr. Taylor is passionate about combining clinical excellence with compassionate, patient-centered care to achieve the best outcomes for his patients.

EDUCATION

• Fellowship (Urologic Oncology): UTSW Medical Center, 07/2022 – 06/2024
• Residency (Urology): NYU Langone Health, 07/2017 – 06/2022
• Medical Degree: Albert Einstein College of Medicine, 08/2013 – 05/2017
• Masters of Public Health: University of Rochester Medical Center, 07/2011 – 05/2013
• Undergraduate degree: University of Rochester, 08/2008 – 05/201

LICENSURE & CERTIFICATIONS

• Texas, T3891 ACLS/BLS Certification

PROFESSIONAL EXPERIENCE

• Attending Physician, Urology Clinics of North Texas, Baylor Scott & White, Dallas, TX, October, 1, 2024
• Assistant Instructor, UTSW Department of Urology, 07/2022 – 06/2024

PROFESSIONAL ACTIVITIES

University Service

• 2019 – 2022 Member – NYU Department of Urology Wellness Committee
• 2015 Teaching Assistant, Anatomy – Albert Einstein College of Medicine
• 2009 – 2011 Head Teaching Assistant – Introduction to Biology, University of Rochester
• 2013 – 2015 Patient Advocate – Albert Einstein College of Medicine

Non-University Service

• 2011 – present Member and former Vice President – Asniya Foundation

Professional and Scholarly Associations

• Member – American Urologic Association
• Member – Society of Urologic Oncologists (SUO)

Professional Association Service

• 2023 – present Committee Member Public Media – AUA

Editorial Service

• 2023 – present Journal of Urology Open Plus
• 2021 – present Journal of Urology
• 2021 – present Bladder Cancer
• 2020 – present World Journal of Surgical Oncology

Honors & Awards

• 2022 SUO-YUO Clinical Trial Development Program Selection
• 2020 Traveling Resident Scholar, AUA Quality Improvement Summit
• 2019 Traveling Resident Scholar Award, IVU Med, Bhopal India
• 2017 Deans Recognition Award, Albert Einstein College of Medicine
• 2015 Funded Travel Award, World Congress of Endourology
• 2014 Summer Research Fellowship, Albert Einstein College of Medicine

PUBLICATIONS

Peer-Reviewed:

• Holland L, Bhanvadia R, Ibeziako N, Taylor J, et al. “Socioeconomic and Demographic Disparities in Immunotherapy Utilization For Advanced Kidney and Bladder Cancer.” Uro Onc, 2024. Accepted for publication.
• Diemling MV, Mertens LS, Furrer M, Taylor, J, the CLIPOLY Study Group et al. “Impact of extent of lymph node dissection on survival outcomes in clinically node-positive bladder cancer.” BJU Int, 2024 Jul; 134(1):119-127. PMID: 38470089.
• Diemling MV, Furrer M, Taylor, J, the CLIPOLY Study Group et al. “Impact of extent of lymph node dissection on survival outcomes in clinically node-positive bladder cancer.” BJU Int, 2024 Mar;133(3):341-350. PMID: 37904652.
• Venishetty N, Taylor J, Xi Y, Howard JM, Ng YS, Wong D, Woldu SL, De Leon AD, Pedrosa I, Margulis V, Bagrodia A. “Testicular radiomics to predict pathology at time of postchemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell tumor.” Clin Genitourin Cancer, 2023 Jul;S1558-7673(23)00169-6. PMID: 37468341.
• Taylor J, Souter L, Barocas DA, Boorjian SA, Raman JD, Lotan Y. “Diagnostic imaging in the evaluation of asymptomatic microhematuria: systematic review and meta-analysis.” J Urol, 2023 Jun;209:1-8. PMID: 36883858.
• Gupta N, Patel H, Taylor J, Borin J, Jacobsohn K, Kenfield S, Eggener S, Price C, Davuluri M, Byrne N, Bivalacqua, Loeb S, “Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes.” Prostate Cancer and Prostatic Dis. 2022 Sep;25(3):444-452. PMID: 35790788.
• Taylor J, Gupta N, Loeb S. “A Systematic Review of Plant-Based Diet and Bladder Cancer: A Call For Further Research.” Société Internationale d’Urologie Journal. 2022 Jul;3(4):240-244. DOI: 10.48083/GBMA2534.
• Xu A, Myrie A, Taylor J, Matulewicz R, Gao T, Pérez-Rosas V, Mihalcea R, Loeb S. “Instagram and prostate cancer: using validated instruments to assess quality of information on social media.” Prostate Cancer and Prostatic Dis. 2022 Apr;25(4):791-793. PMID: 34853412.
• Taylor J, Becher E, Wysock JS, Lenis AT, Litwin MS, Jipp J, Langenstroer P, Johnson S, Bjurlin MA, Tan HJ, Lane BR, Huang WC. “Primary Robot-assisted Retroperitoneal Lymph 2/2024 Node Dissection for Men with Nonseminomatous Germ Cell Tumor: Experience from a Multiinstitutional Cohort.” Eur Urol Focus. 2021 Nov;7(6):1403-1408. PMID: 32682794
• Xu A, Taylor J, Gao T, Mihalcea R, Perez-Rosas V, Loeb S. “TikTok and Prostate Cancer: Misinformation and Quality of Information using Validated Questionnaires.” BJU Int. 2021 Oct;128(4):435-437. PMID: 33811424.
• Taylor J, Weiner A, Wang B, Balar A, Steinberg GD, Matulewicz RS. “Lung metastases versus second primary lung cancers in patients with primary urothelial carcinoma of the bladder: A national population-based assessment.” Bladder Cancer. 2021 Aug;7(3):347-354. DOI: 10.3233/BLC-21008.
• Brake L, Myrie A, Zhao C, Feuer Z, Taylor J, Bjurlin MA, Sherman SE, Makarov DV, Matulewicz RS. “Population-level assessment of smoking-related beliefs and behaviors among survivors of genitourinary cancers: an application of the theory of planned behavior.” Urology. 2021 Aug;154:215-220. PMID: 33577901.
• Loeb S, Mihalcea R, Perez-Rosas V, Xu A, Taylor J, Byrne N, Walter D, et al. “Leveraging Social Media as a Thermometer to Gauge Patient and Caregiver Concerns: COVID-19 and Prostate Cancer.” Eur Urol Open Sci, 2021 Jan 22;25:1-4. PMID: 34337497.
• Loeb S, Taylor J, Borin JF, Mihalcea R, Perez-Rosas V, Byrne N, Chiang AL, Langford A. “Fake News: Spread of Misinformation about Urologic Conditions on Social Media.” Eur Urol Focus. 2020 May 15;6(3):437-439. PMID: 31874796.
• Cacciamani GE, Shakir A, Gill K, Han J, Ahmadi N, Hueber PA, Gallucci M, Simon G, Campi R, Vignolini G, Huang WC, Taylor J, et al. “Best Practices in near-infrared fluorescence imaging with indocyanine green (NIRF/ICG)-guided robotic urologic surgery: systematic reviewbased on expert consensus.” World J Urol. 2020 Apr;38(4):883-896. PMID: 31286194.
• Taylor J, Loeb S. “Guideline of guidelines: social media in urology.” BJU Int. 2020 Mar;125(3):379-382. PMID: 31631471.
• Taylor J, Meng X, Renson A, Smith AB, Wysock JS, Taneja SS, Huang WC, Bjurlin MA. “Different models for prediction of radical cystectomy postoperative complications and care pathways.” Ther Adv Urol, 2019 Sep;11:1756287219875587. PMID: 31565072.
• Ke Y, Taylor J, Gao L, Wang H, Zhao H, Byrne N, Modgil V, Butaney M, Makarov DV, Prabhu V, Loeb S. “Twitter response to the 2018 US Preventative Services Task Force guidelines on prostate cancer screening.” BJU Int. 2019 Sep;124(3):363-364. PMID: 30811805.
• Loeb S, Taylor J, Butaney M, Byrne NK, Gao L, Soule HR, Miyahira AK. “Twitter-based Prostate Cancer Journal Club (#ProstateJC) Promotes Multidisciplinary Global Scientific Discussion and Research Dissemination.” Eur Urol. 2019 May;75(5):811-882. PMID: 30711329.
• Keehn A, Ludmir E, Taylor J, Rabbani F. “Incidence of bladder cancer after radiation for prostate cancer as a function of time and radiation modality.” World J Urol. 2017 May;35(5):713-720. PMID 27629559.
• Keehn A, Taylor J, Lowe F. “Phytotherapy for Benign Prostatic Hyperplasia.” Curr Urol Rep. 2016 Jul;17(7):52. PMID: 27180172.
• Keehn A, Maiman R, Agalliu I, Taylor J, Ghavamian R. “Outcomes and Management Considerations in Patients on Dialysis Undergoing Laparoscopic Radical Nephrectomy for Renal-Cell Carcinoma.” J Endourol. 2015 Jun;29(6):691-695. PMID: 25423552.
• Keehn A, Srivastava A, Maiman R, Taylor J, DiVito J, Ghavamian R, Stern JM. “The relationship between visceral obesity and the clinicopathologic features of patients with small renal masses.” J Endourol. 2015 Mar;29(3)372-376 PMID: 25203393.

Invited Reviews, Letters, Editorials:

• Tachibana I, Qin Q, Taylor J, et al. “Use of Systemic Therapy in the Perioperative Setting for Renal Cell Carcinoma.” J Uro Onc, 2024. Accepted for publication. 2/2024
• Dru Annapureddy, Taylor J. Editorial comment for Wong et al. “A Propensity Score-Matched Analysis of the Impact of Carcinoma in Situ on the Clinical Outcomes in Patients with Upper Tract Urothelial Carcinomas — A Nationwide Multi-Institutional Cohort Study.” JU Open Plus, 2024 Jan 2(1):e00007.
• Levi Holland, Taylor J. Editorial comment for Fores et al. “Do phosphodiesterase type 5 inhibitors (PDE5I) increase the risk of biochemical recurrence after radical prostatectomy?” J Urol, 2024 Mar;21(3):406. PMID:38194478.
• Gold S, Taylor J, Margulis V. “RCC with inferior vena cava thrombus: did we make progress in oncologic outcomes and complications?” Curr Opin Urol, 2023 Mar 1;33(2):142-146. PMID: 36621845.
• Taylor J, Lotan Y. Editorial Comment for Pedersen et al. “Outpatient Photodynamic Diagnosis guided Laser Destruction of Bladder. Tumors is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial.” Eur Urol. 2023 Feb;83(2):131-132. PMID: 36153249.
• Taylor J, Margulis V. Editorial Comment for Rachubinski et al. “Precision-guidance vs. Systematic Sampling: Optimizing Biopsy Assessment of Secondary Prostate Cancer Suspicious Multiparametric Magnetic Resonance Imaging Lesions.” J Urol. 2022 Dec;208(6):1212. PMID: 36097865.
• Feuer Z, Taylor J, Huang WC. The Contemporary Role of Metastasectomy in the Management of Metastatic RCC.” J Cancer Metastasis Treat. 2021 Dec;7:68. DOI: 10.20517/239404722.2021.164.
• Taylor J. Editorial Comment for Raman et al. “The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma.” J Urol. 2021 Dec;206(6):1389. PMID: 34521219.
• Jericevic D, Taylor J, Huang WC. Short commentary “Influence of Clinical Risk Factors on Outcomes in Clinical Stage I men with Non-seminomatous Germ Cell Tumor Undergoing Robotic-Assisted Retroperitoneal Lymph Node Dissection.” Arch Cancer Biol Ther. 2020 Nov;1(3):64-67. DOI: 10.33696/cancerbiology.1.014.
• Taylor J and Matulewicz RS. Editorial Comment for Kriegmair et al. “Multiparametric cystoscopy: opportunities to improve bladder cancer detection.” Transl Androl Urol 2020 Oct;9(5):2302-2304. PMID: 33209700.
• Taylor J, Becher E, Steinberg GD. “Update on the guideline of guidelines: non-muscle invasive bladder cancer.” BJU Int. 2020 Feb;125(2):197-205. PMID: 31597003.
• Taylor J, Meng X, Ghandour R, Margulis V. “Advancements in the clinical management of upper tract urothelial carcinoma.” Expert Rev Anticancer Ther. 2019 Dec;19(12):1051-1060. PMID: 31770492.
• Taylor J, “Prostate Cancer Academy 2019 Selected Summaries.” Rev Urol 2019;21(4):166-171. PMID: 32071565.

Book Chapters:

• Taylor, J, Margulis M, Lotan Y. “Hinman’s Atlas of Urologic Surgery, 5th Edition” In press.

Unpublished Investigations:

• Master’s Thesis: Self-reported facilitators and barriers to trail use along an urban community trail, 2013

Conference Presentations:

• Holland L, Ibeziako N, Taylor J, Woldu S et al. “Socioeconomic and Demographic Disparities in Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma.” AUA 2024
• Bhanvadia R, Taylor J, Bagrodia A, Margulis V et al. “A Safety Net for Safety Net Hospitals: Affiliation with Cancer Centers Impoves Survival in Metastatic Genitourinary Cancers Among the Medically Vulnerable.” AUA 2024
• Bhanvadia R, Taylor J, Bagrodia A, Margulis V et al. “Overcoming Medical Vulnerability: Cancer Center Partnership Associated with Improved Outcomes for Bladder Cancer.” AUA 2024
• Von Deimling M, Mertens L, Taylor J, Pradere B et al. “The optimal number of induction cycles in clinically lymph node-positive bladder cancer.” AUA 2024
• Zappia J, Yong C, Taylor J, Sundaram C et al. “Survival outcomes by race across different continents following minimally invasive surgical treatment for upper tract urothelial carcinoma: an analysis of the ROBUUST registry.” AUA 2024
• TJ Nelson, MF Meagher, Taylor J, A Bagrodia et al. Impact of Chemotherapy on anxiety, depression, and suicidality amongst testicular cancer survivors. GU ASCO 2023 and AUA 2024.
• Taylor J, Kamat A, Lotan Y et al. “Further BCG vs. sequential intravesical gemcitabine and docetaxel therapy in BCG-unresponsive non-muscle invasive bladder cancer: results from a large multi-center cohort.” Podium at SUO 2023.
• Taylor J, Kamat A, Lotan Y et al. “Long term outcomes of bladder sparing therapy compared to upfront radical cystectomy in BCG-unresponsive non-muscle invasive bladder cancer in an international cohort.” Podium at SUO 2023.
• Annapureddy D, Taylor J, Lotan Y et al. “Natural history of bladder sparing therapy in patients with BCG-unresponsive disease; results from a large multi-center cohort.” SUO 2023.
• Annapureddy D, Taylor J, Lotan Y et al. “Oncologic outcomes of gemcitabine-docetaxel combination intravesical bladder sparing therapy compared to upfront radical cystectomy in BCG-unresponsive non-muscle invasive bladder cancer.” SUO 2023.
• Bochner E, Taylor J, Lotan Y et al. “Imaging performance for genitourinary cancers in a large academic institution hematuria population without previous urologic evaluation.” SUO 2023.
• Bochner E, Taylor J, Lotan Y et al. “Risk-based hematuria referral patterns at a large academic institution in patients with no previous urologic evaluation.” SUO 2023.
• Holland L, Taylor J, Woldu S et al. “Socioeconomic and demographic disparities in immunotherapy for advanced clear cell renal cell carcinoma.” SUO 2023
• Bhanvadia R, Taylor, J Woldu S et al. “Socioeconomic and demographic disparities in administration of immunotherapy for advanced urothelial carcinoma of the bladder.” SUO 2023.
• Venishetty N, Taylor J, Xi Y, Howard J, Ng YS, Bagrodia A. “Testicular radiomics correlated with pathology at time of post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell tumor.” AUA 2023.
• Morales-Grimany R, Delgado C, Baky F, Taylor J, et al. “Molecular characteristics and actionable targets of testicular germ cell tumors in real-world conditions.” AUA 2023.
• Zappia J, Yong C, Wu Z, Wang L, Taylor J, ROBUUST Collaborative et al. “Survival Outcomes by race following minimally invasive surgical treatment for upper tract urothelial carcimoma: an analysis of the ROBUUST registry.” AUA 2023
• Corsi N, Morrison C, Davis M, Taylor J, ROBUUST Collaborative et al. “Radical Therapy for Low-Risk Upper Tract Urothelial Carcinoma (ROBUUST Collaborative Group).” AUA 2023.
• Dhanji S, Liu F, Hakimi K, Taylor J, ROBUUST Collaborative et al. “Hypertension is associated with worsened oncologic survival outcomes in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: analysis of the ROBUUST Registry.” AUA 2023.
• Taylor J, Howard J, Xi Y, Ng YS, Bagrodia A. “Testicular radiomics correlated with pathology at time of postchemotherapy retroperitoneal lymph node dissection for non-seminomatous germ cell tumor.” Poster at SUO 2022, GU ASCO 2023.
• Taylor J, Woldu S, Labbate C, Murray KS, Lotan Y et al. “Early Experience of UGN-101 For the Treatment of Upper Tract Urothelial Cancer – A Multi-Center Evaluation of Practice Patterns and Outcomes.” SUO 2022.
• Persily J, Taylor J, Huang R, Taneja SS. “Baseline Selection of Prostate Cancer Active Surveillance Candidates by MRI and MRI-targeted Biopsy Results in Low Rates of Pathologic Re-classification Among Men with Stable MRI and PSA in Follow-up.” Podium at AUA 2021, Las Vegas, NV.
• Myrie A, Brake L, Zhao C, Feuer Z, Taylor J, Bjurlin MA, Matulewicz RS. “Population-level assessment of knowledge and perceptions of the Risk of Bladder Cancer Compared with Other Health-Related Complications of Smoking.” Poster at SUO 2020, virtual.
• Taylor J, Becher E, Wysock JS, Lenis AT, Litwin MS, Jipp J, Langenstroer P, Johnson S, Bjurlin MA, Tan HJ, Huang WC. “Primary Robot-assisted Retroperitoneal Lymph Node Dissection for Men with Nonseminomatous Germ Cell Tumor: Experience from a Multiinstitutional Cohort.” Poster at SUO 2019, Washington DC
• Taylor, J, Meng XS, Renson A, Smith A, Wysock J, Taneja S, Huang W, Bjurlin M. “Different Models for Prediction of Radical Cystectomy Post-operative Complications and Care Pathways.” Poster at the SUO 2018, Phoenix AZ.
• Aboumohamed A, Watts K, Moazami S, Taylor J, Pogash D, Khan M, Agalliu I, Ghavamian R. “Low utilization of adjuvant therapy for adverse pathologic features following radical prostatectomy in African Americans does not translate to an increased risk of biochemical recurrence.” Moderated poster AUA 2016, San Diego CA.
• Keehn A, Ludmir E, Taylor J, Rabbani F. “Incidence of Bladder Cancer After Radiation For Prostate Cancer As A Function Of Time and Radiation Modality.” Moderated Poster AUA 2016, San Diego CA.
• Keehn A, Taylor J, Divito J, Agaillu I, Stern JM, Ghavamian R. “The Relationship Between Perirenal Fat and the Clinicopathologic Features of Patients with Small Renal Masses. Moderated Poster at WCE 2015, London UK.
• Keehn A, Taylor J, Ghavamian R. “Partial Nephrectomy For Endophytic T1b Lesions.” Moderated Video WCE 2015, London UK.
• Keehn A, Taylor J, Ghavamian R. “Tracking Nephron Sparing Surgery: The 50 Most Referenced Articles in Partial Nephrectomy.” Poster WCE 2014, Taipei Taiwan.
• Keehn A, Taylor J, Ghavamian R. “Robotic Assisted Partial Nephrectomy In a Solitary Remnant.” Moderated video WCE 2014, Taipei Taiwan.

• Genitourinary cancer
• Bladder cancer
• Kidney cancer
• Prostate cancer
• Testicular cancer
• Sarcoma
• Kidney stones
• Enlarged prostate
• Ureteral stricture
• Erectile dysfunction
• Low testosterone
• Overactive bladder
• Urethral stricture

• Cystectomy
• Prostatectomy
• MRI Fusion Biopsy
• High Intensity Focused Ultrasound Ablation of Prostate (HIFU)
• Partial Nephrectomy
• Robotic surgery
• IVC Tumor Thrombectomy
• Penectomy
• Retroperitoneal Lymph Node Dissection
• Vasectomy
• GreenLight laser prostatectomy
• SpaceOAR
• Transurethral resection of prostate (TURP)
• Ureteroscopic laser lithotripsy for stones
• Vasectomy